title: Integration of Trastuzumab, with or without  Pertuzumab, into Perioperative Chemotherapy of HER2-  Positive Stomach Cancer: The INNOVATION Trial  (EORTC-1203-GITCG).
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005743:Gastrectomy / Q000379:methods*; D006801:Humans; D038622:Internationality; D008297:Male; D019990:Perioperative Care / Q000379:methods; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D000068878:Trastuzumab / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab